Profhilo is an injectable treatment containing a high concentration of stabilised hyaluronic acid, designed to address age-related skin laxity, volume depletion, and structural dermal decline. It functions as a biostimulant, encouraging the body’s natural collagen and elastin production, which may help improve skin integrity and tissue quality over time.
In clinically appropriate cases, Profhilo may be recommended to support skin affected by environmental damage, early signs of atrophic change, or dehydration-related dermal thinning. By enhancing dermal density and hydration, it can contribute to the maintenance of skin health and structural support. All patients are assessed by a qualified healthcare professional, and treatment is only offered where there is a clear clinical rationale. Suitability depends on a full medical consultation, including consideration of skin condition, overall health status, and treatment history.
Profhilo is administered only by qualified medical professionals, trained in aesthetic and skin health procedures. Treatment may be offered as part of a medical skin health plan, particularly where non-invasive intervention is indicated for early degenerative or inflammatory skin changes. Where appropriate, ongoing treatment is monitored for clinical outcomes, and follow-up consultations may be scheduled to assess patient response and adjust care plans.
